GlassScriptPhysician profile
Ameeth Vedre
NPI 1578643474
$10,267.01
in general payments reported to CMS, 2019-2025
44 companies · $1,385 in 2025
The $1,385 reported for 2025 was more than what 77% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $466 · 2020: $1,053 · 2021: $1,532 · 2022: $1,539 · 2023: $2,694 · 2024: $1,599 · 2025: $1,385.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,217 · Travel and Lodging: $441 · Education: $19.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,216.93 |
| Travel and Lodging | $441.12 |
| Education | $19.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,308.45 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $1,148.26 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $1,037.27 | 2019-2024 | Xarelto |
| Pfizer INC. | $833.05 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $747.28 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $731.71 | 2021-2025 | Verquvo |
| Abbott Laboratories | $687.65 | 2021-2025 | Cardiomems |
| E.R. Squibb & Sons, L.L.C. | $514.30 | 2019-2025 | Camzyos, Eliquis |
| Amarin Pharma, INC. | $455.04 | 2020-2021 | |
| Alnylam Pharmaceuticals INC. | $340.71 | 2020-2025 | Onpattro, Amvuttra, Givlaari |
| Medtronic, INC. | $253.97 | 2021-2024 | Linq II |
| Boehringer Ingelheim Pharmaceuticals, INC. | $227.22 | 2022-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $221.45 | 2020-2025 | Wainua, Farxiga |
| Cvrx, INC. | $214.16 | 2022-2024 | Barostim Neo System |
| Abiomed | $192.75 | 2025 |
Show all 38 companies
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ameeth Vedre listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.